

CANDIDURIA IN A PUBLIC HOSPITAL OF SÃO PAULO (1999-2004): CHARACTERISTICS OF THE YEAST ISOLATES

Elza Helena da SILVA, Luciana da Silva RUIZ, Flavia Emi MATSUMOTO, Marcos Ereno AULER, Mauro Cintra GIUDICE, Débora MOREIRA,
Walderez SZESZS & Claudete Rodrigues PAULA

SUMMARY

The study involved 100 yeast isolates, obtained from urine samples provided by a Public Pediatric Hospital of São Paulo, Brazil, from 1999 to 2004. The most frequent species was *Candida albicans*, followed by *C. tropicalis*, *C. glabrata* and *C. parapsilosis*. In regard to virulence, 97% of the isolates showed index 3 for proteinase and 63% index 2 for phospholipase. The most frequent killer biotypes were 511 and 888.

KEYWORDS: Candiduria; Nosocomial infections; Epidemiological markers.

INTRODUCTION

In the last 20 years, there has been a significant rise in the occurrence of nosocomial infections due to *Candida* genus yeasts. Lately, this increase has been much more associated to urinary tract infections^{5,10}.

The incidence of fungemia and urinary tract infections is gradually on the rise and is an important public health problem. About 10 to 15% of urinary tract hospital infections are due to *Candida* spp., and its prevalence is still increasing^{2,47}. Recent studies have shown that the rate of the urinary tract infection has increased from 0.9/1000 to 2.0/1000 patients^{1,3,33}.

At the end of the 1980s, in the United States, 7% of the total number of nosocomial urinary infections were caused by *Candida* species⁴⁵.

A one-year yeast study conducted with 205 hospitalized patients, showed that, in cases of urinary infection, 22% of the isolates belonged to genus *Candida*²⁰.

Recent studies related to urinary infections caused by *Candida* spp. have focused on specific predisposing conditions, however, particularly for children, candiduria frequency, characteristics and implications are still unknown²⁴. Nevertheless, candiduria can be a precocious marker of a disseminated candidiasis, as demonstrated in a recent study of patients in a Surgical Intensive Care Unit precociously diagnosed with candiduria, who progressed to candidemia. Candiduria has developed in 1.3 - 10% of the patients who previously had funguria, and 0.4% of them evolved to death⁴³.

Many researches showed that candiduria cases not reflect a disseminated candidiasis but colonization or lower urinary tract infection^{4,24}. Often it is difficult to distinguish asymptomatic candiduria from bladder or renal infection. Urine cultures positive for *Candida* species have been noted in healthy men and women^{4,14}.

In the present study, 100 yeast isolates obtained from children with candiduria were identified, and their virulence factors (proteinase and phospholipase) and killer phenotypes were investigated.

MATERIAL AND METHODS

Source of yeasts: This study involved 100 isolates of yeasts obtained from confirmed cases of candiduria in children (zero to seven years) hospitalized in the period from 1999 till 2004 in a Public Pediatric Hospital in São Paulo City, SP, Brazil. This tertiary care hospital, mainly attending a low-income population, has 90 patient beds.

Inclusion criterion: To be considered urinary yeast infection, the yeasts have to be isolated from urine samples with counts superior to 10⁴ UFC/mL for only one isolate and 10⁵ UFC/mL for more than one isolate^{14,21}.

Yeasts identification: The yeasts were identified according to their macroscopic, microscopic and physiological characteristics, according to KURTZMAN & FELL²³. For the identification of *Trichosporon* genus, the classification recommended by GUEHO *et al.*¹⁵ was used.

Proteinase research: Proteinase enzyme research was carried out according to RÜCHEL *et al.*³⁷. The enzyme activity (PZ) was measured

according to PRICE *et al.*³⁵ (Pz = 1 - absence of enzyme activity = index 1; 1.0 < Pz ≤ 0.64 - positive enzyme activity = index 2; Pz < 0.64 - strongly positive enzyme activity = index 3). *C. albicans* pattern strain ICB-12A was used as a positive control.

Phospholipase analysis: Phospholipase enzyme testing was carried out according to PRICE *et al.*³⁵. *C. albicans* pattern strain ICB-12A was used as a positive control.

Susceptibility to killer toxins: The *Candida* isolates' susceptibility to killer toxins was investigated by the technique described by POLONELLI *et al.*³⁶. Nine pattern strains of killer-toxin producers, from Parma University, Italy, were used as a control.

RESULTS

The most frequent species were *Candida albicans*, 56.0%, followed by *C. tropicalis* (20.0%), *C. glabrata* (11.0%), *C. parapsilosis* (4.0%), *C. lusitaniae*, *C. guilliermondii*, *C. krusei* (2.0%) and *Trichosporon asahii* (3.0%).

In regard to the production of extracellular enzymes, 84.0% of all the isolates showed strongly positive activity for proteinase (index 3), and 40.0% of these presented the same index for phospholipase activity. Of the *C. albicans* isolates, 98.2% were proteinase producers and 17.8% did not present phospholipase activity. All the non-*albicans* species showed proteinase production. Of the 43 non-*albicans* isolates, 24 (55.8%) did not produce phospholipase. In regard to the three *Trichosporon asahii* isolates, it was observed that only one was a proteinase producer, while all of them did not produce phospholipase (Table 1).

The tests for susceptibility to killer toxins resulted in eight different biotypes. Of all 100 isolates, the most frequent biotypes were 511 (63.0%) and 888 (20.0%). The biotypes 513 and 555 were all *C. albicans*, while *T. asahii* revealed only biotype 888 (Table 2).

DISCUSSION

The frequency of urinary tract infection caused by yeasts has increased greatly over the last two decades due to the greater prevalence

Table 1

Proteinase and phospholipase activity presented by 100 yeast isolates obtained from cases of candiduria in children hospitalized in a Public Hospital of São Paulo, Brazil (1999-2004)

Yeast species	Enzymatic Indexes							
	1n (%)		2n (%)		3n (%)		TOTAL	
	PA	PPA	PA	PPA	PA	PPA	PA	PPA
<i>C. albicans</i> (56)	1(1.8)	10(17.8)	8(14.2)	12(21.4)	47(83.9)	34(60.8)	55(98.2)	46(82.1)
<i>C. tropicalis</i> (20)	-	12(60)	4(20)	5(25)	16(80)	3(15)	20(100)	8(40.0)
<i>C. glabrata</i> (11)	-	6(54)	-	2(18)	11(100)	3(28)	11(100)	5(45.4)
<i>C. parapsilosis</i> (04)	-	3(75)	-	1(25)	4(100)	-	4(100)	1(25)
<i>C. lusitaniae</i> (02)	-	1(50)	1(50)	1(50)	1(50)	-	2(100)	1(50)
<i>C. krusei</i> (02)	-	2(100)	-	-	2(100)	-	2(100)	-
<i>C. guilliermondii</i> (02)	-	-	-	2(100)	2(100)	-	2(100)	2(100)
<i>T. asahii</i> (03)	2(67)	3(100)	-	-	1(33)	-	1(33)	-
Total (%) (100)	3(3.7)	37(37)	13(13)	23(23)	84(84)	40(40)	97(97)	63(63)

PA = proteolytic activity; PPA = phospholipase activity

Table 2

Sensitivity to killer toxins of 100 isolates obtained from cases of candiduria in patients hospitalized in a Public Pediatric Hospital of São Paulo, Brazil (1999-2004)

Species	Biotypes								Total
	511	513	555	587	812	887	888	111	
<i>C. albicans</i>	46	01	-	01	01	-	05	02	56
<i>C. tropicalis</i>	14	-	01	03	-	-	02	-	20
<i>C. glabrata</i>	02	-	-	02	-	01	06	-	11
<i>C. parapsilosis</i>	-	-	-	02	-	-	02	-	04
<i>C. lusitaniae</i>	-	-	-	-	-	01	-	01	02
<i>C. krusei</i>	-	-	-	-	-	-	02	-	02
<i>C. guilliermondii</i>	01	-	-	-	01	-	-	-	02
<i>T. asahii</i>	-	-	-	-	-	-	03	-	03
Total	63 (63.0%)	01 (1.0%)	01 (1.0%)	08 (8.0%)	02 (2.0%)	02 (2.0%)	20 (20.0%)	03 (3.0%)	100 (100.0%)

of prolonged hospitalization, patients with advanced age, immunocompromised patients; use of antibiotics; prophylaxis by antifungal agents; use of urinary catheters; urinary tract surgical manipulation and, especially, longer stays in intensive care units³. Catheterized patients are at special risk, since around 26% of the urinary tract infections are caused by fungus⁴².

EMORI & GAYNES⁹ and JARVIS¹⁷ reported that 25% of the urinary tract infections are due to *Candida* genus yeasts. *Candida albicans* accounts for 40 to 65% of the fungi isolated from candiduria cases³¹. However, there has been an increase in the incidence of other species, and recently it has been observed that the urinary tract is more frequently colonized by non-*albicans* species than are other sites. The non-*albicans* species include most notably *C. glabrata*, *C. tropicalis*, *C. parapsilosis*, *C. krusei*, *C. lusitaniae* and *Trichosporon* spp.³³.

A survey conducted from 1990 to 1991 of the aetiological agents in urine collected in a tertiary care hospital found a 34% rise in non-*albicans* species and a 11% decrease in *C. albicans*³¹. KRCMÉRY & KOVACICOVÁ²², in a 10-year study, also verified that although *C. albicans* was still the most frequently isolated species, there had been an increase of non-*albicans* species from 1% in 1991 to 46.3% in 1998. *Candida albicans* was identified in 61.6% of all the fungemia cases, followed by *C. parapsilosis* (9.9%), *C. krusei* (5.8%), *C. tropicalis* (4.1%) and *C. glabrata* (3.2%).

In the present study, *C. albicans* was the species most frequently isolated, representing 56% of all the yeasts. However, other species were isolated and the second-most frequent was *C. tropicalis* (20%), followed by *C. glabrata* (11%). During the period from 1998 to 1999, WEINBERGER *et al.*⁴⁷ studied 751 patients with candiduria and found that *C. albicans* was the most common species, with an incidence of 56.4%, followed by *C. tropicalis* (19%) and *C. glabrata* (15%). Other recent studies have also observed that *C. albicans* is still the most commonly isolated species, followed by *C. tropicalis*^{20,27,30}. Lately, studies have shown that *C. glabrata* is the second most isolated species in candiduria cases^{19,40}.

Significant geographic variations on the etiological pattern of invasive *Candida* spp. infections have been reported in various countries. In North America there is a predominance of *C. glabrata* among non-*albicans* species, in South America, however, *C. parapsilosis* and *C. tropicalis* are the predominant ones⁸.

These data have been confirmed by statistical studies performed in South America that have shown the relevance of invasive infections due to *C. parapsilosis* and *C. tropicalis*^{12,13,27,39}. The reasons for this inversion of the species' distribution pattern have not yet been completely elucidated, but may be related to the microorganisms virulence potential and resistance to antifungals⁸.

For the *Candida* genus, one of the most studied virulence factors is the production of extracellular enzymes, such as the secreted aspartyl proteinase (SAPs) that hydrolyse peptide bonds, along with the phospholipases, which hydrolyse phospholipides²⁹.

Various studies have demonstrated that *Candida albicans* and other species are proteinase and phospholipase producers, underscoring the

role that these enzymes play as virulence determinants, regardless of the site from which they are isolated^{26,27,34,39}. According to IBRAHIM *et al.*¹⁶, *Candida albicans* seems to be the only *Candida* species which produces phospholipase *in vitro*. That study also evaluated the ability of various *Candida* spp. species to produce phospholipase, and found that while 79% of the 41 *C. albicans* isolates produced this enzyme, this was not the case for any of the *C. tropicalis*, *C. glabrata* or *C. parapsilosis* isolates. MATSUMOTO *et al.*²⁷, studying the production of phospholipase in *Candida* obtained from catheter and blood, found that while 87.5% of the *C. albicans* isolates produced this enzyme, only three non-*albicans* isolates did. KANTARCIOGLU *et al.*¹⁸ verified that while 62.1% of the non-*albicans* isolates showed phospholipase activity, 93.3% of the *C. albicans* isolates did. RUIZ *et al.*³⁹ observed phospholipase production in 48.3% of *C. albicans* isolates and in 2.7% of the non-*albicans* ones.

In the present study, a higher phospholipase activity was also observed for *C. albicans* (82%), in comparison to non-*albicans* (41%) and *T. asahii* (33%) isolates. This enzyme may also be used as a marker in the diagnosis of candidiasis¹¹.

In regard to proteinase, the enzymatic activity of *C. albicans* isolates ranged from 62.5% to 100%. Experimentally, mutants deficient in terms of proteinase production seem to be less virulent to animals than their proteolytic relatives⁴⁶.

The literature has demonstrated distinct levels of proteinase production by different *C. albicans* isolates and different *Candida* species. Moreover, a correlation has been demonstrated between the level of proteinase production and virulence by species, in descending order: *C. albicans*, *C. tropicalis*, *C. parapsilosis*, *C. krusei*, *C. glabrata* and *C. guilliermondii*^{25,37,38}.

SILVA *et al.*⁴² isolated *C. albicans* from the oral mucosa of patients with AIDS and verified proteinase production in 100% of the isolates. MATSUMOTO *et al.*²⁷ studied 80 *Candida* isolates obtained from blood and catheter and observed that 81.3% presented proteolytic activity. A study performed by RUIZ *et al.*³⁹ demonstrated a strong proteinase activity in *Candida* species: 100% for *C. albicans* and 97.8% for non-*albicans*, isolated from blood. In the present study, 98% of the *C. albicans* and 100% of non-*albicans* species presented strong proteinase activity.

Among the 100 isolates of the present study eight different killer biotypes were found. The biotype most frequently encountered was 511 (63% of all the isolates), representing 82.1% of the *Candida albicans* and 70.0% of the *Candida tropicalis*. Biotype 888, the second-most frequent, was observed in *Candida glabrata* (54.5%) and *Candida parapsilosis* (50.0%).

RUIZ *et al.*³⁹ demonstrated six killer biotypes, while POLONELLI *et al.*³⁶, CANDIDO *et al.*⁶ and MATSUMOTO *et al.*²⁷ registered, respectively, 25, 23 and seven different biotypes. These differences might be related to the variety of anatomical sites from which the yeast samples were taken. Moreover, some studies have found a lower number of killer biotypes than were encountered in these studies^{7,32}.

The most frequent biotypes, 511 and 888, were also prevalent in

89.6% of the *Candida* species isolated from the blood of hospitalized patients²⁵, so they are not restricted only to the urine.

According to MORACE *et al.*²⁸, the use of the killer system for differentiating isolates of pathogenic yeast species can be a useful method for dealing with the nosocomial infections caused by these microorganisms.

RESUMO

Candiduria em hospital público de São Paulo (1999-2004): características das leveduras isoladas

Estudou-se 100 amostras de leveduras, isoladas de urina, provenientes de Hospital Público Infantil de São Paulo Brasil, no período de 1999-2004. A espécie mais freqüente foi *Candida albicans*, seguida de *C. tropicalis*, *C. glabrata* e *C. parapsilosis*. Em relação à virulência, 97% dos isolados apresentaram índice 3 para proteinase e, 63% índice 2 para fosfolipase. Os biótipos “killer” mais freqüentes foram o 511 e 888.

REFERENCES

1. ALMIRANTE, B.; RODRIGUEZ, D.; PARK, B.J. *et al.* - Epidemiology and predictors of mortality in cases of *Candida* bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. **J. clin. Microbiol.**, **43**: 1829-1835, 2005.
2. ALVAREZ-LERMA, F.; NOLLA-SALAS, J.; LEON, C. *et al.* - Candiduria in critically ill patients admitted to intensive care medical units. **Intensive Care Med.**, **29**: 1069-1076, 2003.
3. BINELLI, C.A.; MORETTI, M.L.; ASSIS, R.S. *et al.* - Investigation of the possible association between nosocomial candiduria and candidaemia. **Clin. Microbiol. Infect.**, **12**: 538-543, 2006.
4. BODEY, G.P. - **Candidiasis - pathogenesis, diagnosis and treatment**. New York, Raven Press, 1993.
5. BRITO, L.R.; GUIMARÃES, T.; NUCCI, M. *et al.* - Clinical and microbiological aspects of candidemia due to *Candida parapsilosis* in Brazilian tertiary care hospitals. **Med. Mycol.**, **44**: 261-266, 2006.
6. CANDIDO, R.C.; FISCHMAN, O.; ZAROR, L. & ITO, I.Y. - Diferenciação de cepas de *Candida albicans* pelo sistema killer. **Rev. Soc. bras. Med. trop.**, **28**: 321-324, 1995.
7. CARAMALAC, D.A. - **Ocorrência de leveduras em parturientes e recém-nascidos: tipagem das amostras de *Candida albicans***. São Paulo, 1995. (Dissertação de Mestrado - Instituto de Ciências Biomédicas II, Universidade de São Paulo).
8. COLOMBO, A.L. & GUIMARÃES, T. - Epidemiology of hematogenous infections due to *Candida* spp. **Rev. Soc. bras. Med. trop.**, **36**: 599-607, 2003.
9. EMORI, T.G. & GAYNES, R.P. - An overview of nosocomial infections, including the role of microbiology laboratory. **Clin. Microbiol. Rev.**, **6**: 428-442, 1993.
10. FAULKNER, B.; CHAKSUPA, D.; MALAS, A. & ROSENCRANCE, J.G. - Persistent candiduria complicating intraureteral stenting: a case report and review of the literature. **W. Va. med. J.**, **99**: 25-27, 2003.
11. GHANNOUM, M.A. - Potential role of phospholipases in virulence and fungal pathogenesis. **Clin. Microbiol. Rev.**, **13**: 122-143, 2000.
12. GODOY, P.; TIRABOSCHI, I.N.; SEVERO, L.C. *et al.* - Species distribution and antifungal susceptibility profile of *Candida* spp. bloodstream isolates from Latin American hospitals. **Mem. Inst. Oswaldo Cruz**, **98**: 401-405, 2003.
13. GOLDANI, L.Z. & MARIO, P.S. - *Candida tropicalis* fungemia in a tertiary care hospital. **J. Infect.**, **46**: 155-160, 2003.
14. GOLDBERG, P.K.; KOZINN, P.G.; WISE, G.J. *et al.* - Incidence and significance of candiduria. **J. Amer. med. Ass.**, **241**: 582-584, 1979.
15. GUÉHO, E.; SMITH, M.T.; DE HOOG, G.S. *et al.* - Contributions to a revision of the genus *Trichosporon*. **Antonie v. Leeuwenhok.**, **61**: 289-316, 1992.
16. IBRAHIM, A.S.; MIRBORD, F.; FILLER, S.G. *et al.* - Evidence implicating phospholipase as a virulence factor of *Candida albicans*. **Infect. Immun.**, **63**: 1993-1998, 1995.
17. JARVIS, W.R. - Epidemiology of nosocomial fungal infections, with emphasis on *Candida* species. **Clin. infect. Dis.**, **20**: 1526-1530, 1995.
18. KANTARCIOGLU, A.S. & YUCEL, A. - Phospholipase and protease activities in clinical *Candida* isolates with reference to the sources of strains. **Mycoses**, **45**: 160-165, 2002.
19. KAUFFMAN, C.A.; VAZQUEZ, J.A.; SOBEL, J.D. *et al.* - The prospective multicenter surveillance study of funguria in hospitalized patients. National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. **Clin. infect. Dis.**, **30**: 14-18, 2000.
20. KOBAYASHI, C.C.B.A.; FERNANDES, O.F.L.; MIRANDA, K.C.; SOUZA, E.D. & SILVA, M.R.R. - Candiduria in hospital patients: a study prospective. **Mycopathologia**, **158**: 49-52, 2004.
21. KOZINN, P.H.; TASCHDJIAN, C.L.; GOLDBERG, P.K. *et al.* - Advances in the diagnosis of renal candidiasis. **J. Urol.**, **116**: 778-780, 1976.
22. KRČMÉRY Jr., V. & KOVACICOVÁ, G. - Longitudinal 10-year prospective survey of fungemia in Slovak Republic: trends in etiology in 310 episodes. The Slovak Fungaemia Study Group. **Diagn. Microbiol. infect. Dis.**, **36**: 7-11, 2000.
23. KURTZMAN, C.P. & FELL, J.W. - **The yeasts: a taxonomic study**. New York, Elsevier, 1998.
24. LUNDSTROM, T. & SOBEL, J. - Nosocomial Candiduria: a review. **Clin. infect. Dis.**, **32**: 1602-1607, 2001.
25. MacDONALD, F. - Secretion of inducible proteinase by pathogenic *Candida* species. **Sabouraudia**, **22**: 79-82, 1984.
26. MAFFEI, C.M.; PAULA, C.R.; MAZZOCATO, T.S. & FRANCESCHINI, S. - Phenotype and genotype in *C. albicans* strains delayed from pregnant women with recurrent vaginitis. **Mycopathologia (Den Haag)**, **137**: 87-94, 1997.
27. MATSUMOTO, F.E.; GANDRA, R.F.; RUIZ, L.S. *et al.* - Yeasts isolated from blood and catheter in children from a Public Hospital of São Paulo, Brazil. **Mycopathologia**, **154**: 63-69, 2002.
28. MORACE, G.; ARCHIBUSACCI, C.; SESTITO, M. & POLONELLI, L. - Strain differentiation of pathogenic yeast by the “killer” system. **Mycopathologia (Den Haag)**, **84**: 81-85, 1984.
29. NAGLIK, J.; ALBRECHT, A.; BADER, O. & HUBE, B. - *Candida albicans* proteinases and host/pathogen interactions. **Cell Microbiol.**, **10**: 915-926, 2004.
30. NUCCI, M. - Candiduria in hospitalized patients: a review. **Braz. J. infect. Dis.**, **4**: 168-172, 2000.
31. OCHIPINTI, D.J.; GUBBINS, P.O.; SCHRECKENBERGER, P. & DANZIGER, L.H. - Frequency pathogenicity and microbiologic outcome of non-*Candida albicans* candiduria. **Europ. J. clin. Microbiol. infect. Dis.**, **13**: 459-467, 1994.
32. OLIVEIRA, E.E.; SILVA, S.C.; SOARES, A.J. *et al.* - Toxinas “killer” e produção de enzima por isolados da mucosa bucal de pacientes com câncer. **Rev. Soc. bras. Med. trop.**, **31**: 523-527, 1998.

33. OLIVEIRA, R.D.; MAFFEI, C.M. & MARTINEZ, R. - Infecção urinária hospitalar por leveduras do gênero *Candida* sp. **Rev. Ass. méd. bras.**, **47**: 321-325, 2001.
34. PAULA, C.R.; SAMPAIO, M.C.C.; BIRMAN, E.G. & SIQUEIRA, A.M. - Oral yeasts in patients with bucal cancer before and during radiotherapy. **Mycopathologia (Den Haag)**, **112**: 119-124, 1990.
35. PRICE, M.F.; WILKINSON, I.D. & GENTRY, L.O. - Plate method for detection of phospholipase in *Candida albicans*. **Saboraudia**, **20**: 7-14, 1982.
36. POLONELLI, L.; ARCHIBUSACCI, C.; SESTITO, M. & MORACE, G. - "Killer" system: a simple method for differentiating *Candida albicans* strains. **J. clin. Microbiol.**, **17**: 774-780, 1983.
37. RÜCHEL, R.; TEGELER, R. & TROST, M.A. - Comparison of secretory proteinases from different strains of *Candida albicans*. **Saboraudia**, **20**: 233-244, 1982.
38. RÜCHEL, R.; UKLEMANN, K. & BONING, B. - Secretion of acid proteinases by different species of the genus *Candida*. **Zbl. Bakt. Hyg. I. Abt. Orig.**, **255**: 537-548, 1983.
39. RUIZ, L.S.; SUGIZAKI, M.F.; MONTELLI, A.C. *et al.* - Fungemia by yeast in Brazil: occurrence and phenotypic study of strains isolated at the Public Hospital, Botucatu, São Paulo. **J. Mycol. Med.**, **15**: 13-21, 2005.
40. SAFDAR, N.; SLATTERY, W.R.; KNASINSKI, V. *et al.* - Predictors and outcomes of candiduria in renal transplant patients. **Clin. infect. Dis.**, **40**: 1413-1421, 2005.
41. SELLAMI, A.; SELLAMI, H.; MAKNI, F. *et al.* - La candidurie en milieu de réanimation: signification et intérêt de la numération des levures dans les urines. **Ann. français. Anesth. Reanim.**, **25**: 584-588, 2006.
42. SILVA, M.R.R., COSTA, M.R., MIRANDA, A.T.B.; FERNANDES, O.F.L. & PAULA, C.R. - Evaluation of Etest and macrodilution broth method for antifungal susceptibility testing of *Candida* sp. strains isolated from oral cavities of AIDS patients. **Rev. Inst. Med. trop. S. Paulo.**, **44**: 121-125, 2002.
43. SIMPSON, C.; BLITZ, S. & SHAFRAN, S.D. - The effect of current management on morbidity and mortality in hospitalised adults with funguria. **J. Infect.**, **49**: 248-252, 2004.
44. SOBEL, J.D.; KAUFFMAN, C.A.; MCKINSEY, D. *et al.* - Candiduria a randomized double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. **Clin. infect. Dis.**, **30**: 19-24, 2000.
45. VOSS, A.; HOLLIS, R.J.; PFALLER, M.A.; WENZEL, R.P. & DOEBBELING, B.N. - Investigation of the sequence of colonization and candidemia in nonneutropenic patients. **J. clin. Microbiol.**, **32**: 975-980, 1994.
46. WALTHER, T.H.; RYTTER, M.; SHONBORN, C. & HAUSTEIN, U.F. - Differences in the intracellular killing of proteinase-positive and proteinase negative *C. albicans* strains by granulocytes. **Mykosen.**, **29**: 154-161, 1986.
47. WEINBERGER, M.; SWEET, S.; LEIBOVICI, L.; PITLIK, S.D. & SAMRA, Z.J. - Correlation between candiduria and departmental antibiotic use. **J. Hosp. infect.**, **53**: 183-186, 2003.

Received: 27 October 2006

Accepted: 23 July 2007